Definitive Contract 75N93019C00037
Award Date
9/1/19
Potential Completion Date
11/30/21
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
HDT Bio Corp
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical...
HDT Bio Corp. was awarded a $11 million cost-plus-fixed-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein bound to lipid inorganic nanoparticle formulation, through a Phase I clinical trial. The contract was awarded under the 2020 NIAID Omnibus Broad Agency Announcement seeking proposals to develop medical countermeasures including vaccines,...
This is a $749,000.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to HDT Bio Corp. The contract supports Research and Development (R&D) on the use of HDT Bio's Lion-ReRNA technology in rapid response vaccine development, specifically for an Accelerated Capabilities Initiative (AOI) focused on "Vaccine on Demand." The...
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $224,992 firm fixed price definitive contract to Hafion Inc., a self-certified small disadvantaged and woman-owned small business, to conduct research and development on generating synergy between protein and non-protein macromolecular adjuvants. The contract, which was not set aside, was completed in July 2018. Hafion has also received other prime and...
This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
This $221,889 firm fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company, for "Diagnostics to Enable Malaria and Neglected Tropical Diseases". The contract originated from the NIH/Centers for Disease Control and Prevention (CDC) Small Business Innovation Research (SBIR) Program Solicitation PHS 2018-1, which sought...
The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $599,980 firm fixed price contract to Tendel Therapies, Inc., a small business, for research and development services related to genetic adjuvants to promote durable anti-influenza stem antibodies in older adults. This contract was awarded under the NIH and Centers for Disease Control and Prevention's Small Business Innovation Research (SBIR) program,...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...